Scinai Immunotherapeutics Ltd. SCNI NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • IL • USD

SharesGrow Score

57/100

2/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Scinai Immunotherapeutics Ltd. (SCNI) has a negative trailing P/E of -0.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -1,115.35%.

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -0.1); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -1,115.35%).
Trailing Earnings Yield -1,115.35% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.

Overall SharesGrow Score: 54/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

57/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

25/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

11/100

→ Income

✓

GROWTH

100/100

→ Income

✓

INCOME

100/100

→ Income

Valuation Snapshot — SCNI

Valuation Multiples

P/E (TTM)-0.1

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.10

P/S Ratio0.60

EV/EBITDA-0.2

Per Share Data

EPS (TTM)$-6.64

Book Value / Share$6.09

Revenue / Share$0.99

FCF / Share$-2.76

Yields & Fair Value

Earnings Yield-1,115.35%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-4.7	0.16	1.70	0.00	-
2017	-2.8	-0.02	1.72	0.00	-
2018	-1.3	-0.02	-3.73	0.00	-
2019	-2.4	-0.30	-4.03	0.00	-
2020	-22.5	0.22	-6.86	0.00	-
2021	-2.9	-0.01	24.55	0.00	-
2022	-1.0	0.02	-3.17	0.00	-
2023	-0.4	0.01	-0.51	0.00	-
2024	0.6	0.00	0.27	4.11	-
2025	-0.2	0.00	0.21	1.27	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2015	$-396,880.00	$0.00	$-2.62M	-
2016	$-282,320.00	$0.00	$-2.38M	-
2017	$-790,280.00	$0.00	$-9.93M	-
2018	$-1,435,800.00	$0.00	$-23.46M	-
2019	$-1,548,800.00	$0.00	$-31.62M	-
2020	$-50,040.00	$0.00	$-1.39M	-
2021	$-320,000.00	$0.00	$-8.21M	-
2022	$-122,960.00	$0.00	$-5.8M	-
2023	$-66,560.00	$0.00	$-6.5M	-
2024	$0.00	$658K	$4.8M	728.9%